The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.
TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.
The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.
If you have any questions you can fill in the form or mail us directly: info@train-heart.eu.
News
Join the ISHR webinar on the Journal of Molecular and Cellular Cardiology's Special Issue on Cardiac Epigenetics: Driving signals to the cardiac epigenome in development and disease. Guest Editors Emma Louise Robinson, Manuel Rosa-Garrido, Chukwuemeka George Anene-Nzelu will host the discussion with two authors from the special issue: Ralf Gilsbach and Justus Stenzig.
See all articles in this special issue at
https://www.sciencedirect.com/journal/journal-of-molecular-and-cellular-cardiology/special-issue/10MGD9M71M5
Speakers:
Dr Ralf Gilsbach
Dr Justus Stenzig
Chairs:
Dr. Emma Louise Robinson
Dr. Manuel Rosa-Garrido
Dr. Chukwuemeka George Anene-Nzelu
Host: Dr Ronald Vagnozzi
Jul 12, 2021 11:00 AM in Eastern Time (US and Canada)
Webinar registration: https://us02web.zoom.us/webinar/register/WN_dhSNb-MwTJeAI-vdOw6tFA
Tue, 25 May
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 813716.
Copyright © 2020
